Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)

2008 ◽  
Vol 51 (4) ◽  
pp. 875-896 ◽  
Author(s):  
Jean-François Bonfanti ◽  
Christophe Meyer ◽  
Frédéric Doublet ◽  
Jérôme Fortin ◽  
Philippe Muller ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Fusion Inhibitor ◽  
Virus Fusion ◽  
Syncytial Virus ◽  
Selection Of ◽  
Clinical Candidate

scholarly journals Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Dirk Roymans ◽  
Sarhad S Alnajjar ◽  
Michael B Battles ◽  
Panchan Sitthicharoenchai ◽  
Polina Furmanova-Hollenstein ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Therapeutic Efficacy ◽  
Fusion Inhibitor ◽  
Virus Fusion ◽  
Syncytial Virus

scholarly journals Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model

2010 ◽  
Vol 38 (2) ◽  
pp. 401-408 ◽  
Author(s):  
W. Olszewska ◽  
G. Ispas ◽  
C. Schnoeller ◽  
D. Sawant ◽  
T. Van de Casteele ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Mouse Model ◽  
Fusion Inhibitor ◽  
Protective Activity ◽  
Virus Fusion ◽  
Syncytial Virus

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

Immunity ◽  
2021 ◽  
Author(s):  
Maryam Mukhamedova ◽  
Daniel Wrapp ◽  
Chen-Hsiang Shen ◽  
Morgan S.A. Gilman ◽  
Tracy J. Ruckwardt ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Antibody Responses ◽  
Virus Fusion ◽  
Syncytial Virus
Sign in / Sign up

Export Citation Format

Share Document